SIGN UP

Sign up to get updates about our clinical trials and other exciting news close

LIGHTING THE WAY
TO A NEW TREATMENT
POSSIBILITY

LIGHTING THE WAY
TO A NEW TREATMENT
POSSIBILITY

At a Glance

The goal of the Illuminate 204 clinical trial is to evaluate whether an investigational study drug called tilsotolimod (IMO-2125) combined with an FDA approved immunotherapy drug (either Yervoy® or Keytruda®) is a safe and effective treatment for patients who have metastatic melanoma.

  • PATIENT ENROLLMENT

    adults who have metastatic melanoma that has
    progressed on or after available approved treatments

  • ENROLLMENT GOAL

    100
    patients

  • STUDY DRUG

    Tilsotolimod (IMO-2125) plus Yervoy® (ipilimumab) or tilsotolimod plus Keytruda® (pembrolizumab)

*Additional eligibility criteria apply. Please contact your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Study overview

The study is being conducted in two phases:

In phase 1, researchers will determine the optimal dose of tilsotolimod (IMO-2125) to give in combination with either Yervoy® (ipilimumab) or Keytruda® (pembrolizumab).

In phase 2, researchers will evaluate the safety and effectiveness of the study drug combinations.

*Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb Company. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Eligibility requirements

You may be eligible to participate in the study if you*

  • are age 18 years or older
  • have a clinical diagnosis of metastatic melanoma (melanoma that has spread to other parts of your body)
  • have melanoma that has progressed on or after treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab)
  • You might not be eligible to participate if you have melanoma in or around the eye, a condition known as ocular melanoma

Before you can be enrolled in a study, you must undergo a process called screening, during which the study team will evaluate whether you qualify to participate.

*Additional eligibility criteria apply. Please speak to your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb Company. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact information

If you would like to learn more about this study or speak with someone on our team, please contact us.

1-877-888-6550 ext. 2 (U.S. toll free) or 484-348-1600